Apigenin is a plant flavonoid which has been shown to significantly inhibit UV-induced mouse skin tumorigenesis when applied topically, and may represent an alternative sunscreen agent in humans. We have investigated the molecular mechanism(s) by which apigenin inhibits skin tumorigenesis. Initial studies examined the effects of apigenin on the cell cycle. DNA flow cytometric analysis indicated that culturing cells for 24 h in medium containing apigenin induced a G2/M arrest in two mouse skin derived cell lines, C50 and 308, as well as in human HL-60 cells. The G2/M arrest was fully reversible after an additional 24 h in medium without apigenin. We investigated the effects of apigenin on cyclin Bl and p34 cdc2 , since cyclin Bl/p34 cdc2 complexes regulate G 2 /M progression. Western blot and immune complex kinase assays using whole cell lysates from 308 and C50 cells treated for 24 h with 0-70 (iM doses of apigenin demonstrated that apigenin treatment did not change the steady-state level of pM" 102 protein, but did inhibit p34 edc2 HI kinase activity in 308 cells. Western blot analysis showed that apigenin treatment of C50 cells and 308 cells inhibited the accumulation of cyclin Bl protein in a dose-dependent manner. The apigenin levels detected in cultured keratinocytes were relevant to those detected in epidermal cells of Sencar mice treated with tumor inhibitory doses of apigenin. In conclusion, we present evidence that apigenin induces a reversible G2/M arrest in cultured keratinocytes, the mechanism of which is in part due to inhibition of the mitotic kinase activity of p34 cdc2 , and perturbation of cyclin Bl levels.
Introduction
Apigenin is a natural, plant flavonoid present in the leaves and stems of vascular plants, including fruits and vegetables (1). It is relatively nontoxic and nonmutagenic in comparison with other flavonoids such as quercetin. Apigenin and other flavonoids are strong antioxidants which exert a number of effects on cell biology (1). A classic example is their ability to scavenge free radicals, which are involved in cell damage and tumor promotion (2) . As a member of the flavonoid family, apigenin is present in foods associated with a decreased risk
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(0 Oxford University Press of cancer, and flavonoids are believed to play an important role in delaying or preventing carcinogenesis, although their mechanism(s) of action is not fully understood.
The chemopreventive aspects of apigenin have been investigated both in vitro and in vivo (3) (4) (5) . Apigenin has been shown to be antimutagenic against nitropyrene-induced genotoxicity in Chinese hamster ovary (CHO*) cells in vitro (3) . In addition, Wei et al. demonstrated that apigenin is a strong inhibitor of ornithine decarboxylase activity, a marker of tumor promotion, induced by TPA in epidermal cells (4) . The flavonoid apigenin has also been shown to increase gap junctions in rat liver epithelial cells, a property which may contribute to its chemopreventive ability by maintaining cell to cell communication (5) .
In vivo studies carried out in our laboratory using the mouse skin two-stage carcinogenesis model initiated by 7,12-dimethylbenz[a]anthracene (DMBA) and promoted with 12-0-tetradecanoylphorbol-13-acetate (TPA), demonstrated that topical application of apigenin significantly reduced the number of benign papillomas and squamous cell carcinomas in SENCAR mice (4) . We also demonstrated that apigenin was equally effective at reducing UV-B radiation-induced squamous cell carcinomas in hairless SKH mice (Birt et al., submitted) .
The antitumor properties of other flavonoids have been studied with respect to apoptosis and the cell cycle. Quercetin and genistein caused apoptosis when cultured with several myeloid and lymphoid cell lines (6) (7) (8) . Other flavonoids have been found to perturb the G\ and G 2 phases of the cell cycle. A recent report by Sato et al. demonstrated that apigenin caused a G 2 /M arrest and induced differentiation in rat neuronal cells (9) . Genistein, an isoconformer of apigenin, was shown to cause a G 2 /M arrest in several human and murine cell lines (6) (7) (8) 10) . Quercetin has been demonstrated to inhibit cell cycle progression at the G r S phase boundary in a human gastric cancer cell line HGC-27 (11). The synthetic flavone L86-8275 was also shown to block cell cycle progression at either G| or G 2 phase depending on the method used to synchronize the cell culture (12) . Questions as to the mechanism of cell cycle arrest by flavonoids and DNA damaging agents remain largely unanswered, but appear to involve multiple cell cycle regulatory proteins.
Cyclin-cyclin dependent kinase (cdk) complexes regulate the passage through the eukaryotic cell cycle checkpoints by initiating a phosphorylation cascade leading to the transcription of genes needed for proliferation, as well as the phosphorylation of nuclear lamins and histones for nuclear membrane breakdown and chromosome condensation, respectively (13) . The G 2 to M phase progression is governed by the cyclin B-p34 cdc2 complex (14) . Cyclin B is expressed during late S and G 2 phase and immediately binds to p34 cdc2 . P34 cdc2 is activated, in part, by binding to cyclin B and by phosphorylation of p34 cdc2 at Thrl61 by the cdk-activating kinase CAK (15) . Cyclin B-p34 cdc2 complexes are negatively regulated until M phase by phosphorylation of Thrl4 and Tyrl5 (the latter residue being phosphorylated by Weel kinase) in the ATP binding domain (16) . At the onset of M phase, the complex is translocated from the cytoplasm to the nucleus in concert with an abrupt increase in HI kinase activity by cyclin B-p34 cdc2 due to the rapid dephosphorylation of Thrl4 and Tyrl5 by the phosphatase cdc25 (17, 18) . Inactivation of cyclin B-p34 cdc2 is required for exit from mitosis and results from ubiquitin-mediated degradation of cyclin B (19) .
Based upon our in vivo studies demonstrating that apigenin was an effective and potent inhibitor of both chemical and UV-induced skin tumorigenesis, we were interested in elucidating the molecular mechanism(s) of apigenin's chemopreventive activity. In view of previous reports by other laboratories that various flavonoids can perturb the cell cycle, we began by investigating the affects of apigenin on the keratinocyte cell cycle and some of the regulatory proteins involved in the G2 to M phase progression.
Materials and methods

Cell culture
C50 cells are an immortalized murine keratinocyte cell line (20). The 308 keratinocyte cell line contains an activated Ha-ras oncogene and forms papillomas upon engraftment in nude mice (21) . C50 and 308 cells were cultured in 0.05 mM Ca 2+ EMEM medium with 8% chelexed fetal bovine serum (FBS). HL-60 human myelogenous leukemia cells were cultured in RPMI-1640 (Gibco, Grand Island, NY) containing 10% FBS.
Cell cycle analysis
Asynchronous C50 and 308 cells were cultured in either 60 or 100 mm dishes to 50% confiuency at which time the culture medium was replaced and an aliquot of apigenin in DMSO was added. Stock solutions of apigenin or genistein (Sigma, St Louis, MO) were dissolved in dimethyl sulfoxide (DMSO) and an aliquot was added to each culture dish to achieve the desired final concentration of apigenin. HL-60 cells were cultured in six-well dishes at a density of 1-3X 10 5 cells/ml in fresh media supplemented with various doses of apigenin (or genistein). Cells were cultured with apigenin or genistein for a minimum of 24 h at 37°C in 5% CO 2 . Control cultures received an equivalent amount of DMSO and it had no measurable effect on the cell cycle for all cell lines tested. After the allotted time in culture, C50 and 308 cells were harvested by trypsin release and resuspended in 1 ml of modified Vindelov's DNA staining solution (10 (ig/ml RNase A, 0.1% Nonidet P-40, 85 u.g/ml propidium iodide, in PBS) 1-2 h prior to flow cytometric analysis. HL-60 cells were collected by centrifugation at 900 rpm for 5 min and resuspended in 1 ml Vindelov's solution. The fluorescence of 10 000 cells was measured with a Becton-Dickinson FAC" Plus flow cytometer with excitation at 488 nm. The percentage of cells in Gl, S, and 62/M phase of the cell cycle was determined using the CellHt Cell-Cycle Analysis computer program version 2.01.2.
Western blot analysis
C50 and 308 cells at 50% confluency were cultured in EMEM containing various doses of apigenin (or DMSO alone) for 24 h with each dish containing the same total amount of DMSO (<0.6% v/v). After 24 h in culture, cells were harvested in 0.4 ml Triton Lysis Buffer (TLB) (20 mM Tns pH 7.4, 137 mM NaCl, 25 mM (J-glycerophosphate, 2 mM EDTA, 1 mM Na 3 VO 4 , 1% triton X-100, 10% glycerol, 1 mM PMSF, 5 ug/ml leupeptin, 5 ug/ml aprotinin, 2 mM benzamidine, and 0.5 mM DTT) using a cell scraper. Whole cell lysates were incubated on ice for 15 min before clearing the insoluble material by centrifugation at maximum speed in a microcentrifuge for 10 min, at 4°C. Protein concentration of supematants was determined using a modified Lowry assay (Biorad). One hundred micrograms of whole cell extract was electrophoresed on 12% SDS-PAGE gels and transferred in 25 mM Tris, 192 mM glycine, 15% methanol, 0.02% SDS to polyvinylidene difluoride (PVDF) membrane (Immobilon-P, Millipore) at 4°C. Rainbow molecular weight markers (Amersham) were visible on the membrane after transfer. Membranes were cut into two pieces horizontally at the 46 kD mark and subsequent steps performed separately. Nonspecific binding sites were blocked for 1 h or overnight in blocking buffer (10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20, and 1% Bovine serum albumin [BSA] ). The lower half of membranes containing proteins <46 kD were first incubated with a 1:1000 dilution of rabbit, polyclonal anti-p34 cdc2 (generously provided by Dr R.Lock) in blocking buffer for 3 h at room temperature. The top portion of membranes 2368 was incubated with a mouse monoclonal anti-Cyclin Bl antibody (Santa Cruz) at a 1:300 dilution in blocking buffer for 1 h at room temperature. Unbound primary antibody was removed with six washes of 5 rain each with wash buffer (blocking buffer minus BSA). Membranes were incubated for 1 h at room temperature with secondary antibody [horse radish peroxidase conjugated goat anti-rabbit IgG (1:3000) or anti-mouse IgG (1:1000; Sigma)] in blocking buffer. Following six washes of 5 min each, bound antibody was detected using enhanced chenuluminescence (Amersham) according to manufacturer's instructions. Membranes were exposed to ECL-Hyperfilm (Amersham).
Immune complex p34
alc2 kinase assays C50 or 308 cells were treated with apigenin and harvested exactly as described above for Western blot analysis. P34 was immunoprecipitated from 100 ng whole cell extract using 0.5 (ig mouse anti-p34 cdc2 (Santa Cruz) prebound to 20 nl Protein A-sepharose. Immunoprecipitation reactions employing antip34«Jc2 were carried out at room temperature for 2 h. Immunoprecipitated complexes were resuspended in H1 kinase reaction mix containing 40 Hi of 20 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 1 mM DTT, 10 mM MgCl 2 , 5 Hi HI solution (1 mg/ml solution in 200 mM NaCl, 0.1 mM EGTA, 1 mM DTT, 20 mM Tris-HCl, pH 7.5, 10 (Jg of both leupeptin and aprotinin), and 1 |il (10 u.Ci) [ 32 PJyATP. Kinase reactions proceeded for 15 min at room temperature and were stopped by the addition of 25 uj 2 X SDS-PAGE loading buffer. Radioactive kinase reaction products were separated by electrophoresis on 10% SDS-PAGE gels, dried under vacuum at 80°C, and exposed to Phosphorimager (Molecular Dynamics). Histone band intensities were quantitated using the Phosphorimager. Relative kinase activities for each treatment were normalized to solvent control.
Apigenin uptake C50 cells were cultured in 100 mm dishes to 50% confluency. The culture medium (10 ml) was replaced with fresh medium and an aliquot of apigenin (with 26.8 Ci/mol [G-
3 H]apigenin) in DMSO or DMSO alone was added to each dish to achieve the predetermined apigenin concentration in the medium. In all experiments, the volume of solvent DMSO was the same for all doses. The cells were cultured in the apigenin-containing medium for a predetermined time at 37°C and 5% CO2-Then the medium was removed and the cells were rinsed with 2X5 ml PBS. After removing the PBS completely, the cells were harvested into ethanol by scraping and homogenized mechanically. Following centrifugation the supernate was saved and the residue was extracted with ethanol for another two times. The ethanol extracts were combined and assayed for radioactivity by scintillation counting. The cell number for each group was obtained from a separate replicate dish. For cell counting, the cells were treated with cold apigenin only and harvested by trypsin release. The apigenin uptake was calculated from the radioactivity, cell number, and percentage of radioactivity associated with apigenin determined by HPLCscintillation analysis. For HPLC-scintillation analysis, the cell extract was injected into HPLC system equipped with Alltima Cl8 column (250X2.1 mm). The column was eluted with 0.1% TEA in H 2 O/acetonitrile (52:48) at a flow rate of 0.3 ml/min. The eluent was collected as 0.5 min fractions and assayed for radioactivity by scintillation counting. The medium was extracted with ether and the extract was converted into ethanol solution for HPLC-scintillation analysis.
Results
Apigenin induced a G-/M arrest in keratinocytes
We investigated the affects of apigenin on the keratinocyte cell cycle using two murine skin cell lines, C50 and 308. Figure la presents the results of the DNA flow cytometric analysis of C50 keratinocytes cultured for 24 h in medium containing various doses of apigenin. As can be seen in Figure  1A , we observed a dose-responsive accumulation of C50 cells in the G2/M phase of the cell cycle after culturing the cells for 24 h in media containing apigenin. Maximum G2/M arrest of C50 cells was achieved with 30 |i.M apigenin treatment. No affect on the cell cycle was observed with medium containing DMSO alone (0 ^lM). We also tested the affect of apigenin on another keratinocyte cell line, the 308 papilloma line. 308 cells were cultured for 24 h in medium containing 10, 30, 50, or 70 }iM apigenin (or DMSO alone). The results in Figure  IB show that 10 and 30 \iM doses of apigenin produced a 25% and 44% G 2 /M accumulation, respectively. No further arrest was achieved at higher doses of 50 and 70 (iM. In order in medium with 18.5 |iM (5 |ig/ml) or 37 |iM (10 (ig/ml) apigenin. Our results as shown in Figure 2 , indicate that 37 \iM apigenin treatment caused a profound G 2 /M arrest in HL-60 cells (up to 93%) compared to solvent control cultures.
G/M arrest by apigenin is reversible
We next determined whether G 2 /M arrest induced by apigenin is reversible. C50 keratinocytes were cultured in medium containing 30 |iM apigenin for 24 h at which time the cultures were washed three times with PBS, replenished with fresh media without apigenin, and returned to the incubator at 37°C for an additional 6, 12, 24, or 36 h. DNA cell cycle analysis of C50 cells harvested at time points post release are depicted in to investigate whether the accumulation of 308 cells in G 2 /M was time-dependent rather than dose-dependent, 308 cells were cultured for 24, 36, and 48 h in medium containing apigenin. Table I immortalization and transformation of human keratinocytes (23) .
Effects of apigenin on p34 cdc2 kinase activity
We next tested the hypothesis that apigenin might induce a G 2 /M arrest by inhibiting p34 cdc2 HI kinase activity. C50 and 308 cells were cultured with increasing doses of apigenin for 24 h as described previously, and whole cell extracts were prepared and assayed for HI kinase activity using an immune complex kinase assay. Results of HI kinase assay of apigenintreated C50 cells in Figure 6A demonstrated a 55% kinase inhibition when the dose of apigenin reached 45 \iM. lower doses of apigenin had no effect on kinase activity in C50 cells. Figure 6B demonstrates the dose responsive inhibition of p34«ic2 kjuase activity by apigenin in 308 cells, with doses of 10, 30, and 50 (iM resulting in cdc2 kinase inhibition by 28%, 88%, and 95%, respectively. These results taken in conjunction with Western blot experiments presented in Figure 5 lead us to conclude that apigenin inhibited p34 cdc2 kinase activity by changing the activation state, rather than altering the amount present.
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Hours Post Release and returned to culture at 37°C for an additional 6, 12, or 24 h. Distinct G 2 /M arrest by both apigenin (85%) and genistein (90%) was evident at 0 h post release ( Figure 4) . As early as 12 h post release the majority of HL-60 cells treated with apigenin had progressed through mitosis and entered Go/G| phase, and by 24 h post release apigenin treated HL-60 cells had resumed a normal cell cycle profile. In contrast, only a small percentage of genistein-arrested HL-60 cells entered GQ/ G| after 24 h. Therefore our results indicate that unlike genistein, apigenin induces a G 2 /M arrest which is fully reversible after 24 h.
Effects of apigenin on p34
cdc2 steady-state levels In view of the fact that the major regulatory cyclin dependent kinase(cdk), p34 cdc2 , is responsible for G 2 to M phase progression in all eukaryotic cells, we next investigated whether apigenin induces G 2 /M arrest by altering the protein level or inhibiting kinase activity of pSi" 102 in keratinocytes. P34 cdc2 is normally present at approximately constant levels throughout the cell cycle, but its kinase activity is cyclically modulated. We performed western blot analysis of cell extracts prepared from apigenin-treated C50 and 308 cells ( Figure 5 ). Our results showed that apigenin treatment did not change the steady-state level of p34 c°c2 compared to DMSO-treated cultures ( Figure  5 ). Western blots indicated a triplet band migrating at 34 kD that is believed to represent different phosphorylated forms of p34 cdc2 (22) . We observed no change in the relative intensity of the triplet bands, which suggests apigenin had no effect on phosphorylation status. Although the steady-state level of p34«ic2 ^ not change w jthjn the same cell line, we observed that 308 cells expressed higher steady-state levels of p34 
Apigenin treatment reduces the steady-state of cyclin Bl protein
We were interested in determining whether or not the G 2 /M arrest and p34 cdc2 kinase inhibition were due to the fact that apigenin may be limiting the supply of cyclin B in apigenintreated keratinocytes. When Western blot analysis was performed with 100 |ig aliquots, we observed no major change in the level of cyclin Bl protein until the highest dose of 45 |iM ( Figure 7A ). However, we noted that the percentage of cells in G 2 /M was increasing with apigenin dose (the percentage of cells in G 2 /M is indicated under each lane in Figure 7 ). When the band intensity of cyclin B1 was normalized to the percentage of cells in G 2 /M, the level of cyclin B1 did not increase as one would expect in a population of cells containing a higher proportion in G 2 /M ( Figure 7B ). In fact, after normalizing the band intensity to the percent of cells in Figure 8B indicated that the uptake of 20 (iM apigenin increased quickly in the first few hours, reached a maximum at 8 h, and remained steady thereafter. HPLCscintillation analysis indicated that 100% of the radioactive isotope recovered from cell extract and medium was apigenin. The effect of apigenin on cell viability was minimal, as tested by trypan blue dye exclusion. Cells treated with 10 | XM apigenin showed no change in viability with respect to control. Cells treated with 30 ^iM, 50 \iM, and 70 \LM were 96%, 96%, and 89% of control viability, respectively. We have also demonstrated that intracellular levels of apigenin are comparable to those achieved in mouse epidermal cells after topical application (manuscript in preparation). 
Discussion
Several epidemiologic studies have demonstrated that the consumption of vegetables correlates negatively with cancer incidence for colon, breast, and lung cancers, as well as other types of cancer (24) (25) (26) . Indoles, thiocyanates, isothiocyanates, and flavonoids such as apigenin, are among the nonnutritive vegetable components identified as having antitumorigenic properties (27) .
We have studied the flavonoid apigenin in vivo using UV-B radiation and DMBA/TPA-induced mouse skin carcinogenesis models, and demonstrated that topical application of 5 |imol apigenin significantly reduced the number of benign papillomas and squamous cell carcinomas (4, Birt et al., submitted) .
A. Apigenin levels used in C50 cells were similar to those we have detected in the epidermal cells in vivo from mice treated topically with 5 (amol apigenin (Li et al., unpublished) . Thus, the fact that similar cellular apigenin concentrations are observed in vitro and in vivo provides a connection between our in vitro mechanistic results and the in vivo chemopreventive activity of apigenin. There was also no evidence for apigenin metabolism in cultured keratinocytes, which is consistent with our in vivo and in vitro metabolism studies with the epidermis of SENCAR mice (Li et al., unpublished) . In the data presented herein, we report that apigenin exerts its chemopreventive activity, in part, by causing a G 2 /M cell cycle arrest in keratinocytes that is fully reversible. Apigenin was effective at causing a reversible G 2 /M arrest in cells at different stages of tumorigenesis and in cells of different lineages. The variation between cell lines in the percent of cells in G 2 /M after a 24 h culture with apigenin may be explained by the fact that 308 cells may also be undergoing a Gr/Gi arrest as well as a G 2 /M arrest. We are currently investigating this possibility with respect to stage of tumorigenesis and sensitivity to apigenin treatment. Worthwhile 2372 noting is the fact that DNA flow cytometric and agarose gel analysis show no signs of apigenin-induced apoptosis in keratinocytes.
To further elucidate the molecular mechanism of apigenin with respect to its ability to cause a G 2 /M cell cycle arrest, we began investigating the major regulatory proteins governing G 2 to M phase progression. We found that apigenin does not alter the steady-state level of the mitotic cdk, p34 cdc2 , in keratinocytes ( Figure 5 ). Since we established that apigenin treatment did not alter the steady-state level of p34 cdc2 , any change in HI kinase activity would accurately reflect changes in activation state, rather than an absence of p34 cdc2 protein present in immune complex kinase assays. We demonstrated that apigenin treatment inhibited p34 cdc2 kinase activity in C50 and 308 keratinocyte cell lines ( Figure 6A and B, respectively) . A dose of 45 U. M apigenin inhibited cdc2 kinase activity by 48%, while 15 (iM and 30 U. M apigenin treatment of C50 cells resulted in a substantial G 2 /M arrest (75%) with little kinase inhibition. Possible explanations for this discrepancy include alterations in cyclin Bl subcellular localization and effects on cyclin Bl/p34cdc2 complex formation. Alternatively, apigenin may produce a G2/M arrest in C50 cells by a mechanism independent of cyclin-cdk involvement, for example by inhibiting microtubule formation.
In contrast to C50 cells, apigenin inhibited cdc2 kinase activity in 308 cells in a dose-dependent manner. Inhibition of kinase activity was apparently not due to perturbation of the cdc2 phosphorylation status, since no evidence for altered band migration was observed in Western blot analysis ( Figure  5 ). Other laboratories using various agents to perturb the cell cycle or damage DNA have noted changes in the phosphorylation state of p34 cdc2 . In CHO cells, etoposide inhibits p34 cdc2 kinase activity and maintains the enzyme in a tyrosine phosphorylated state (28) . Tyrosine phosphorylation of p34 cdc2 is also evident in HL-60 cells after they are subjected to ionizing radiation (29) . In contrast, a decrease in tyrosine phosphorylated p34 cdc2 is observed with G 2 arrest by the synthetic flavone L86-8275 (30) . Thus, the mechanistic differences in inducing G 2 /M arrest may be due to the activity of other cell cycle regulatory proteins. To date there have been no described cyclin dependent kinase inhibitors of p34 cdc2 in vivo (14) .
The first requirement for G 2 to M phase progression is that cyclin B must accumulate above a threshold level during G 2 to enter mitosis (31) . Without adequate levels of cyclin B present, cells arrest in G 2 . For example, Maity et al. demonstrated this checkpoint feature by y-irradiating HeLa cells, which resulted in a reduction of cyclin Bl protein and subsequent G 2 block (32). They further reported that decreased RNA stability contributes to the reduction in cyclin B1 mRNA following y-irradiation and subsequent G 2 delay (32). Our results presented herein indicate that the level of cyclin Bl protein is reduced in apigenin-treated C50 and 308 cells when normalized to the percent of cells in G 2 /M (Figure 7) . We do not yet know whether this reduction in cyclin B protein is due to an effect on cyclin B mRNA. Studies are in progress to investigate this possibility since during a normal cell cycle the level of cyclin Bl mRNA parallels that of the protein, which starts to rise in S phase, peaks in G 2 /M phase and then rapidly disappears in early Gl (33) .
Equally as important as the transcription and stability of cyclin B1 mRNA is the programmed degradation of cyclin B1 protein at the metaphase-anaphase transition, which is a required event for cells to exit mitosis (19) . A predominant A.
B. theory is that cyclin degradation occurs by ubiquitin-mediated proteolysis (34) . Although the signal transduction events leading to ubiquitin-mediated cyclin destruction are unresolved, it is plausible that apigenin causes aberrant cyclin B1 degradation by perturbing a ubiquitin signal transduction cascade. Experiments are underway to determine if the lack of cyclin Bl protein in apigenin-treated cells is due to transcriptional, posttranscriptional, or post-translational regulation. Gi/S and G2/M checkpoint controls prevent the acquisition of multiple genetic changes by ensuring that DNA is repaired before replication in S phase and properly segregated during M phase of the cell cycle, respectively. The majority of cancers characterized to date have defects in at least one cell cycle checkpoint For example, p53 is a tumor suppressor gene that is frequently mutated, especially in human skin cancer (35) . P53 has been extensively studied for its role in inducing the p21WAFl/CIPl cdk inhibitor, which results in G, arrest following DNA damage (36, 37) . Incompletely replicated and damaged DNA signals a G 2 /M arrest in order to prevent mutations, translocations, and/or chromosome loss. Attenuation of this G 2 delay has recently been demonstrated to precede immortilization of human fibroblasts (38) . Furthermore, the loss of important cell cycle checkpoints selects cells that have not only a growth advantage but also a predisposition for acquiring more chromosome aberrations. Cancer cells that lose cell cycle checkpoints evolve into drug resistant, invasive, and metastatic variants (39) . In light of our results that apigenin causes a G2/M arrest, the essence of apigenin's chemopreventive activity may be to slow cancer development by ensuring that sufficient intrinsic and artificially imposed cell cycle checkpoints exist in the presence of DNA damaging and tumor promoting agents. By deciphering the molecular mechanisms of apigenin, it may be possible to interfere with cancer development through good nutrition or local delivery of purified fiavonoids, especially for those who are genetically predisposed to certain types of cancer (40) . Also in view of the fact that apigenin may represent an alternative sunscreen agent in humans, studies to further define apigenin's molecular mechanism of chemoprevention are warranted.
